Figure 3 Multi-hit model for autoimmune diseases

Slides:

Advertisements

Similar presentations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Advertisements

Figure 2 Response after initial increase in total tumour burden

Figure 1 Role of innate lymphoid cells (ILCs) in steady state,

Figure 4 Tissue infiltration and lymphadenopathy in patients with CTLA4 mutations Figure 4 | Tissue infiltration and lymphadenopathy in patients with CTLA4.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Connexins in cartilage

Figure 1 Historical evolution of the clinical classification and

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Induction of immune tolerance

Figure 2 Binding properties of P2Y12-receptor inhibitors

Figure 2 Heat map of targeted therapies in autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Involvement of SEMA4D in the pathogenesis

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 1 Schematic comparison of expected

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA

Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 7 Defects in apoptosis

Figure 3 Nucleic acid sensors in SLE

Figure 5 Regulation of inflammation by metabolites

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Figure 4 Approaches to targeting inhibitory immune receptors

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Algorithm for the determination of the clinical

Figure 2 Overlap of associated loci among five rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Statistical approaches for the analysis of metabolomic data

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Figure 3 Cell-surface markers for NP cell differentiation

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 1 Simplified EULAR and GRAPPA

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 The current model of the pathogenesis of SLE

Figure 1 A hierarchy of steps need to be

Figure 1 Reproductive health in patients with rheumatic diseases

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Chronic inflammation and DNA damage in people with SLE

Figure 3 Nuclear-penetrating autoantibodies and synthetic lethality

Figure 2 Phenotypes of osteoarthritis

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Figure 2 The main effects of adipokines on bone remodelling in osteoarthritis Figure 2 | The main effects of adipokines on bone remodelling in osteoarthritis.

Presentations of thyroid disorders after receiving immune checkpoint inhibition combination therapy or monotherapy. Presentations of thyroid disorders.

Nat. Rev. Rheumatol. doi: /nrrheum

Presentation transcript:

Figure 3 Multi-hit model for autoimmune diseases Figure 3 | Multi-hit model for autoimmune diseases. Clinical symptoms that occur after the initial hits in the development of autoimmune rheumatic disease still wane, whereas accumulation of hits leads to stable irreversible disease. Immune checkpoint inhibition (not shown) can be considered as a hit in this context, as checkpoint-blocking therapies cause immune-related adverse effects that resemble autoimmune phenomena in some patients. van der Vlist, M. et al. (2016) Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.131